Jefferies Group Comments on Minerva Neurosciences Inc’s Q1 2018 Earnings (NERV)
Minerva Neurosciences Inc (NASDAQ:NERV) – Research analysts at Jefferies Group issued their Q1 2018 earnings estimates for Minerva Neurosciences in a report issued on Monday. Jefferies Group analyst B. Amin expects that the biopharmaceutical company will post earnings per share of ($0.30) for the quarter. Jefferies Group also issued estimates for Minerva Neurosciences’ Q2 2018 earnings at ($0.35) EPS, Q3 2018 earnings at ($0.39) EPS, Q4 2018 earnings at ($0.41) EPS and FY2022 earnings at ($0.08) EPS.
A number of other research analysts have also issued reports on the stock. ValuEngine lowered shares of Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. BidaskClub upgraded shares of Minerva Neurosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Minerva Neurosciences currently has an average rating of “Hold” and an average target price of $12.92.
In other news, CFO Geoff Race sold 5,829 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $5.79, for a total transaction of $33,749.91. Following the completion of the sale, the chief financial officer now owns 197,698 shares of the company’s stock, valued at approximately $1,144,671.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 12,590 shares of company stock valued at $73,073. 21.60% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors lifted its holdings in shares of Minerva Neurosciences by 861.1% during the 3rd quarter. Nationwide Fund Advisors now owns 124,990 shares of the biopharmaceutical company’s stock worth $950,000 after acquiring an additional 111,985 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Minerva Neurosciences by 14.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,074,239 shares of the biopharmaceutical company’s stock worth $9,507,000 after acquiring an additional 134,942 shares during the period. Northern Trust Corp lifted its holdings in shares of Minerva Neurosciences by 27.9% during the 2nd quarter. Northern Trust Corp now owns 298,507 shares of the biopharmaceutical company’s stock worth $2,641,000 after acquiring an additional 65,056 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in shares of Minerva Neurosciences by 69.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 84,245 shares of the biopharmaceutical company’s stock worth $746,000 after acquiring an additional 34,572 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in shares of Minerva Neurosciences during the 3rd quarter worth approximately $2,835,000. 70.20% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/03/14/jefferies-group-comments-on-minerva-neurosciences-incs-q1-2018-earnings-nerv.html.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.